http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Surface-Effect-Induced Optical Bandgap Shrinkage in GaN Nanotubes
Park, Young S.,Lee, Geunsik,Holmes, Mark J.,Chan, Christopher C. S.,Reid, Benjamin P. L.,Alexander-Webber, Jack A.,Nicholas, Robin J.,Taylor, Robert A.,Kim, Kwang S.,Han, Sang W.,Yang, Woochul,Jo, Y. American Chemical Society 2015 NANO LETTERS Vol.15 No.7
<P>We investigate nontrivial surface effects on the optical properties of self-assembled crystalline GaN nanotubes grown on Si substrates. The excitonic emission is observed to redshift by ∼100 meV with respect to that of bulk GaN. We find that the conduction band edge is mainly dominated by surface atoms, and that a larger number of surface atoms for the tube is likely to increase the bandwidth, thus reducing the optical bandgap. The experimental findings can have important impacts in the understanding of the role of surfaces in nanostructured semiconductors with an enhanced surface/volume ratio.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/nalefd/2015/nalefd.2015.15.issue-7/acs.nanolett.5b00924/production/images/medium/nl-2015-00924p_0006.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/nl5b00924'>ACS Electronic Supporting Info</A></P>
Direct imaging of the electron liquid at oxide interfaces
Song, Kyung,Ryu, Sangwoo,Lee, Hyungwoo,Paudel, Tula R.,Koch, Christoph T.,Park, Bumsu,Lee, Ja Kyung,Choi, Si-Young,Kim, Young-Min,Kim, Jong Chan,Jeong, Hu Young,Rzchowski, Mark S.,Tsymbal, Evgeny Y.,E Nature Publishing Group UK 2018 Nature nanotechnology Vol.13 No.3
<P>The breaking of symmetry across an oxide heterostructure causes the electronic orbitals to be reconstructed at the interface into energy states that are different from their bulk counterparts(1). The detailed nature of the orbital reconstruction critically affects the spatial confinement and the physical properties of the electrons occupying the interfacial orbitals(2-4). Using an example of two-dimensional electron liquids forming at LaAlO3/SrTiO3 interfaces(5,6) with different crystal symmetry, we show that the selective orbital occupation and spatial quantum confinement of electrons can be resolved with subnanometre resolution using inline electron holography. For the standard (001) interface, the charge density map obtained by inline electron holography shows that the two-dimensional electron liquid is confined to the interface with narrow spatial extension (similar to 1.0 +/- 0.3 nm in the half width). On the other hand, the two-dimensional electron liquid formed at the (111) interface shows a much broader spatial extension (similar to 3.3 +/- 0.3 nm) with the maximum density located similar to 2.4 nm away from the interface, in excellent agreement with density functional theory calculations.</P>
Publisher Correction: Direct imaging of the electron liquid at oxide interfaces
Song, Kyung,Ryu, Sangwoo,Lee, Hyungwoo,Paudel, Tula R.,Koch, Christoph T.,Park, Bumsu,Lee, Ja Kyung,Choi, Si-Young,Kim, Young-Min,Kim, Jong Chan,Jeong, Hu Young,Rzchowski, Mark S.,Tsymbal, Evgeny Y.,E Nature Publishing Group UK 2018 Nature nanotechnology Vol.13 No.7
In the version of this Letter originally published, in two instances in Fig. 1 the layers in the cross-sectional view of the (001) interface were incorrectly labelled: in Fig. 1b SrO<SUP>+</SUP> should have read SrO<SUP>0</SUP>; in Fig. 1c LaO<SUP>+</SUP>, AlO<SUB>2</SUB><SUP>–</SUP>, LaO<SUP>+</SUP>, TiO<SUB>2</SUB><SUP>0</SUP>, SrO<SUP>+</SUP>, TiO<SUB>2</SUB><SUP>0</SUP> should have read LaO<SUB>3</SUB><SUP>3–</SUP>, Al<SUP>3+</SUP>, LaO<SUB>3</SUB><SUP>3–</SUP>, Ti<SUP>4+</SUP>, SrO<SUB>3</SUB><SUP>4–</SUP>, Ti<SUP>4+</SUP>. In Fig. 3c the upper-right equation read –σ<SUB>s</SUB> = –e/2a<SUP>2</SUP> but should have read –σ<SUB>s</SUB> = e/2a<SUP>2</SUP> and in Fig. 3f the lower-right equation read –σ<SUB>s</SUB> = –e/2√3a<SUP>2</SUP> but should have read σ<SUB>s</SUB> = –e/2√3a<SUP>2</SUP>. These errors have now been corrected in the online version of the Letter.
Yongwhi Park,Si Wan Choi,Ju Hyeon Oh,Eun-Seok Shin,Sang Yeub Lee,Jeong Su Kim,김원,Jeong-Won Suh,Dong Heon Yang,Young Joon Hong,Mark Y Chan,Jin Sin Koh,Jin-Yong Hwang,Jae-Hyeong Park,Young-Hoon Jeong 대한심장학회 2019 Korean Circulation Journal Vol.49 No.7
Background and Objectives: Impaired recovery from left ventricular (LV) dysfunction is a major prognostic factor after myocardial infarction (MI). Because P2Y12 receptor blockade inhibits myocardial injury, ticagrelor with off-target properties may have myocardial protection over clopidogrel. In animal models, ticagrelor vs. clopidogrel protects myocardium against reperfusion injury and improves remodeling after MI. We aimed to investigate the effect of ticagrelor on sequential myocardial remodeling process after MI. Methods: High platelet inhibition with ticagrelor to improve LV remodeling in patients with ST-segment elevation MI (HEALING-AMI) is an investigator-initiated, randomized, open-label, assessor-blinded, multi-center trial done at 10 sites in Korea. Patients will be enrolled if they have ST-segment elevation MI (STEMI) treated with primary percutaneous coronary intervention and a planned duration of dual antiplatelet treatment of at least 6 months. Screened patients will be randomly assigned (1:1) using an internet-based randomization with a computer-generated blocking with stratification across study sites to either ticagrelor or clopidogrel treatment. The co-primary primary endpoints are LV remodeling index with three-dimensional echocardiography and the level of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) at 6 months representing post-MI remodeling processes. Changes of LV end-systolic/diastolic volume indices and LV ejection fraction between baseline and 6-month follow-up will be also evaluated. Analysis is per protocol. Conclusions: HEALING-AMI is testing the effect of ticagrelor in reducing adverse LV remodeling following STEMI. Our trial would show the benefit of ticagrelor vs. clopidogrel related to the recovery of post-MI LV dysfunction beyond potent platelet inhibition. Trial Registration: ClinicalTrials.gov Identifier: NCT02224534